For Immediate Release:

Contact: Allen & Caron Inc   CLOSURE Medical Corp
  Joe Allen (investors) Len Hall (media) Benny Ward, CFO
  (212) 691-8087 (949) 474-4300 (919) 876-7800
  joe@allencaron.com len@allencaron.com  

CLOSURE MEDICAL RECEIVES MEDICAL DESIGN EXCELLENCE AWARD

RALEIGH, NC (April 13, 2004)… CLOSURE Medical Corporation (Nasdaq:CLSR), a global leader in biomaterial-based medical devices, announced today that it has received a Medical Design Excellence Award from Canon Communications, the publisher of Medical Device & Diagnostic Industry Journal, for its design of the DERMABOND ProPen XL Applicator System.

The DERMABOND ProPen XL Applicator System provides physicians with greater precision application and control of adhesive flow utilizing the High-Viscosity DERMABOND Topical Skin Adhesive. The device is a disposable, sterile, single-use medical delivery system, which is used by healthcare professionals as a replacement for sutures and staples when closing incisions and lacerations. All DERMABOND products are distributed by ETHICON, INC., a Johnson & Johnson Company.

The Medical Design Excellence Awards competition is the only awards program that exclusively recognizes contributions and advances in the design of medical products. Products are evaluated on design and engineering features incorporating innovative use of materials, user-related features that improve healthcare delivery and change traditional medical attitudes or practices, features that provide enhanced benefits to the patient and the ability of the product development team to overcome design and engineering challenges so the product meets its clinical objectives. A comprehensive review of the entries was performed by an impartial, multidisciplinary panel of third-party judges with expertise in biomedical engineering, human factors, industrial design, medicine, diagnostics, and medical packaging.

“We are honored to be recognized by the Medical Design Excellence Awards for the DERMABOND ProPen XL Applicator System,” said William M. Cotter, Vice President of Operations and Project Leader for ProPen XL. “We are dedicated to developing and manufacturing products that fulfill the unmet needs of healthcare providers and patients and feel that the ProPen XL product has greatly enhanced the ease of use for physicians and practitioners.”

The 2004 Medical Design Excellence Award recipients will be honored at a ceremony during the Medical Design & Manufacturing East 2004 Conference and Exposition, June 15-17, 2004 at New York City’s Jacob K. Javits Convention Center. Gold and Silver award recipients will be announced at this time.


MORE-MORE-MORE

About CLOSURE Medical Corporation
CLOSURE Medical Corporation is a global leader in the development and manufacture of innovative biomaterial-based medical devices that fulfill the needs of healthcare practitioners, patients and consumers.

For additional information on CLOSURE Medical visit its website at www.closuremed.com or visit the "Clients" section of the Allen & Caron website at www.allencaron.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties or other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance, or other expectations implied by these forward-looking statements. These factors include, but are not limited to the early stage of commercialization of the Company’s products; the progress of its research and development programs for future products; the need for regulatory approval and effects of governmental regulation; technological uncertainties; the satisfactory conclusion of negotiations with, and dependence on marketing partners, and dependence on patents and trade secrets, as well as those detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2003, filed with the Securities and Exchange Commission. Although the Company believes that the expectations in the forward-looking statements are reasonable, the Company cannot guarantee such results. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.